Venture Capital

Berlin-based Tacalyx is advancing its lead drug, TCX-201, to the clinic, targeting a novel class of antigens once thought impossible to drug.

A new stem cell therapy promises a one-time cure for hemophilia A, and the FDA is clearing the path. Could lifelong, costly infusions become a memory?

The Defense Logistics Agency has awarded a landmark $50M contract to Corsha to rapidly deploy identity-based Zero Trust security across its critical OT systems.

As DLH Holdings prepares its Q2 results, investors watch to see if it can navigate contract losses and prove its mettle in the federal tech space.

With patient enrollment accelerating for its novel lung fibrosis drug, LTI-03, Rein Therapeutics signals progress in a field desperate for new options.

Oral care leader quip and skincare giant Glowbar partner, signaling a major shift toward simplified, habit-driven wellness. What does this mean for you?

Seattle startup CounterX Therapeutics to present its novel overdose prevention drug at a top investor event, signaling new hope in the fentanyl crisis.

Snap CEO Evan Spiegel will headline Augmented World Expo, unveiling new tools from subsidiary Specs Inc. and charting a course for human-empowered spatial AI.

The largest deal in epigenetic testing sees TruDiagnostic's parent buy Dr. David Sinclair's Tally Health, aiming to make personalized longevity mainstream.

The U.S. Highbush Blueberry Council is betting on startups to find new uses for blueberries in everything from skincare to pet food. Here's what's next.

With a new industry giant on its board and fresh funding, Phagenesis is set to scale its groundbreaking neuromodulation therapy for swallowing disorders.

Shanghai's Vivacta Bio raises over $50M from top VCs to revolutionize cancer treatment with its pioneering in vivo CAR-T therapy, GT801.

A novel, FDA-cleared wound therapy is rolling out to military and veteran hospitals, aiming to rewrite the rules of healing for the most complex injuries.

MindBio's new tech detects intoxication from your voice, promising safer workplaces but sparking major debate over surveillance, bias, and data privacy.

Scottish biotech EnteroBiotix secures major funding to advance its gut therapy for IBS-C, offering new hope for a disease-modifying treatment.

Metals Australia unveils a major graphite refinery in Baie-Comeau, promising a huge economic boost and a key role in the West's critical mineral strategy.

A record-breaking investment in AI for war ignites a fierce debate over autonomous weapons and the future of global conflict in the age of robots.

Elmo Motion Control's new EASIII software aims to streamline complex motion programming, boosting efficiency and safety in next-generation smart factories.

A new short film features a lifelike robotic dog, sparking conversations about AI's role in mental wellness and the complex future of companionship.

A new patent-pending platform embeds force plates directly into sports surfaces, promising to revolutionize athlete analytics, coaching, and fan engagement.